Antipsychotic Medications in Youth

Antipsychotic medications in youth refers to the use of agents that act principally by blocking dopamine D2 receptors, increasingly the second-generation drugs, to treat psychosis, mania, and a range of behavioral indications such as irritability and aggression in children and adolescents. Their pediatric use has expanded well beyond psychotic disorders, which is why their efficacy for specific indications and their pronounced metabolic effects are central to how the evidence is read.

Definition

Antipsychotic medications in youth are psychotropic drugs that reduce psychotic, manic, and severe behavioral symptoms in children and adolescents, acting chiefly through dopamine D2 receptor blockade, with second-generation agents also affecting serotonergic and other receptors.

Scope

The entry covers the main indications studied in young people, the distinction between first- and second-generation agents, the evidence for efficacy in conditions such as autism-associated irritability, and the metabolic and cardiometabolic risks that distinguish pediatric prescribing. It treats antipsychotics as an evidence and methodology topic within pediatric psychopharmacology, not as treatment guidance.

Core questions

• For which pediatric indications, beyond psychosis, is antipsychotic efficacy actually established?
• How large and how rapid are the metabolic and cardiometabolic effects in first-time pediatric users?
• How should the benefits for behavioral indications such as irritability be weighed against metabolic harms?

Key concepts

• Dopamine D2 receptor blockade
• First- versus second-generation antipsychotics
• Irritability and aggression as treatment targets
• Autism-associated behavioral problems
• Weight gain and metabolic syndrome
• Cardiometabolic monitoring
• Off-label pediatric prescribing

Mechanisms

Antipsychotics act primarily by antagonizing dopamine D2 receptors, which underlies their effect on psychotic and manic symptoms; second-generation agents additionally modulate serotonergic and other receptors, a profile associated with a different side-effect pattern. Several of these receptor actions, including effects on histaminergic and serotonergic systems, are implicated in appetite stimulation and weight gain, which in children and adolescents can appear rapidly and be accompanied by adverse changes in lipids and glucose regulation, as documented when these drugs are used for the first time.

Clinical relevance

Antipsychotic prescribing to youth is a leading example of the tension between symptomatic benefit and metabolic harm: trials such as the RUPP Autism Network study show clear efficacy for irritability in autism, while first-time-use cohorts document rapid weight gain and metabolic change, motivating systematic monitoring. This entry explains how that evidence is generated and weighed; it describes the field and is not a basis for individual prescribing decisions.

Epidemiology

Use of second-generation antipsychotics in children and adolescents rose markedly in many countries from the late 1990s, with much of the growth driven by non-psychotic indications such as disruptive behavior and aggression. A large share of pediatric use is off-label, and prescribing varies by setting, with higher rates reported among some publicly insured and foster-care populations.

History

First-generation antipsychotics were used in severely disturbed children from the mid-twentieth century, but their neurological side effects limited use. The arrival of second-generation agents broadened pediatric prescribing, and the 2002 RUPP Autism Network trial of risperidone established efficacy for serious behavioral problems in autism. As use expanded, the 2009 Correll cohort of first-time pediatric users quantified rapid weight gain and metabolic change, shifting attention toward routine cardiometabolic monitoring.

Debates

Expanding use for behavioral indications

Antipsychotics are widely prescribed to youth for aggression and irritability rather than psychosis, and whether this is justified given the metabolic risks and the availability of psychosocial alternatives remains contested.

Severity and reversibility of metabolic effects

First-time pediatric use is associated with rapid weight gain and adverse metabolic changes, and how to balance these against symptomatic benefit, and how reversible they are, is a continuing concern.

Seminal works

• mccracken-2002
• correll-2009

Frequently asked questions

Why are antipsychotics prescribed to children who do not have psychosis?

Beyond psychosis and mania, some second-generation antipsychotics have trial evidence for reducing severe irritability and aggression, for example in autism, which has driven much of their expanding pediatric use; this describes the evidence and is not treatment advice.

What is the main safety concern with antipsychotics in youth?

First-time use in children and adolescents is associated with rapid weight gain and adverse changes in lipids and glucose, which is why metabolic monitoring is emphasized when these medications are studied and used.